U.S. Markets close in 4 hrs 21 mins
  • S&P 500

    4,155.85
    +20.91 (+0.51%)
     
  • Dow 30

    33,992.95
    +171.65 (+0.51%)
     
  • Nasdaq

    13,864.21
    +77.94 (+0.57%)
     
  • Russell 2000

    2,216.47
    +28.26 (+1.29%)
     
  • Crude Oil

    61.87
    -0.80 (-1.28%)
     
  • Gold

    1,794.20
    +15.80 (+0.89%)
     
  • Silver

    26.53
    +0.69 (+2.67%)
     
  • EUR/USD

    1.2041
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    1.5780
    +0.0160 (+1.02%)
     
  • Vix

    17.88
    -0.80 (-4.28%)
     
  • GBP/USD

    1.3943
    +0.0006 (+0.0432%)
     
  • USD/JPY

    108.0730
    +0.0030 (+0.0028%)
     
  • BTC-USD

    56,031.70
    +100.05 (+0.18%)
     
  • CMC Crypto 200

    1,289.69
    +26.73 (+2.12%)
     
  • FTSE 100

    6,898.54
    +38.67 (+0.56%)
     
  • Nikkei 225

    28,508.55
    -591.83 (-2.03%)
     

Recro to Present at H.C. Wainwright Global Life Science Conference

  • Oops!
    Something went wrong.
    Please try again later.
Recro Pharma, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright Global Life Science Conference. The conference, which will take place March 9-10, 2021, is being conducted with a virtual format.

Details for the corporate presentation are as follows:

  • H.C. Wainwright Global Life Science Conference
    Details: Recro management will deliver a corporate presentation and participate in 1-on-1 meetings
    Conference dates: March 9-10, 2021
    Format: Virtual conference

About Recro
Recro (NASD: REPH) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.

For more information about Recro’s CDMO solutions, visit recrocdmo.com.

CONTACT: Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Recro (484) 395-2436 ryan.lake@recroCDMO.com